Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SOPHiA GENETICS ( (SOPH) ) just unveiled an update.
On November 4, 2025, SOPHiA GENETICS SA released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a revenue increase compared to the previous year, but it also experienced a significant loss for the period. This financial update reflects the company’s ongoing investment in research and development, as well as selling and marketing efforts, which are crucial for its growth and competitive positioning in the biotechnology sector.
The most recent analyst rating on (SOPH) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.
Spark’s Take on SOPH Stock
According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.
SOPHiA GENETICS shows strong technical momentum and positive developments from the latest earnings call, including revenue growth and strategic partnerships. However, significant financial performance challenges, particularly in profitability and cash flow, weigh heavily on the overall score. The valuation remains unattractive due to ongoing losses.
To see Spark’s full report on SOPH stock, click here.
More about SOPHiA GENETICS
SOPHiA GENETICS SA is a company operating in the biotechnology industry, focusing on data-driven medicine. It provides genomic and radiomic analysis services, aiming to enhance clinical diagnostics and research through its cloud-based platform.
Average Trading Volume: 105,835
Technical Sentiment Signal: Buy
Current Market Cap: $337.9M
See more data about SOPH stock on TipRanks’ Stock Analysis page.